Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Janux Therapeutics, Inc. (JANX)

Janux Therapeutics CMO William Go departs; company begins search for successor

Neutral Impact 3 of 5 leadership Written later

On June 23, 2026, Chief Medical Officer William Go left Janux Therapeutics. The company determined the departure was a termination without Cause under its Change in Control and Severance Benefit Plan. Janux has started a search for a successor, and existing clinical leaders will cover his responsibilities in the interim, with the company saying its development strategy, regulatory plans and previously disclosed clinical timelines are unaffected.

Key points

  • Departure of William Go, M.D., Ph.D., as Chief Medical Officer effective June 23, 2026
  • Company classified the exit as a termination without Cause under its Change in Control and Severance Benefit Plan
  • Search for a successor has begun; members of the existing clinical leadership team are assuming his duties in the interim
  • Company states the departure was not the result of any disagreement on operations, policies or practices

The filing

CompanyJanux Therapeutics, Inc. (JANX)
Form8-K, current report
Filed with the SECJun 23, 2026, 4:05 PM ET
Accession number0001193125-26-279428

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.